Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus

被引:11
|
作者
Peleg, Noam [1 ,2 ]
Schmilovitz-Weiss, Hemda [1 ,2 ]
Shamah, Steven [1 ,2 ]
Schwartz, Ariel [3 ]
Dotan, Iris [1 ,2 ]
Sapoznikov, Boris [1 ,2 ]
机构
[1] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Dept Pathol, Petah Tiqwa, Israel
关键词
DIAGNOSIS; MANAGEMENT; CANCER; GUIDELINES; DYSPLASIA; SURVIVAL;
D O I
10.1055/a-1292-8747
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patient's with Barrett's esophagus (BE) are at risk of progression to esophageal adenocarcinoma (EAC). Neutrophil to lymphocyte ratio (NLR) was found to be a predictor of poor prognosis in patients with EAC; however, its performance in premalignant esophageal lesions is vague. We aimed to evaluate the utility of NLR as a predictor of histologic progression in patients with BE. Methods A prospective cohort of patients with proven BE in a tertiary referral center was retrospectively analyzed. All biopsies were reviewed by an expert gastrointestinal pathologist. The discriminatory capacity of NLR was evaluated by area under the receiver operating characteristic (AUC) curve analysis and Cox regression analysis. Results 324 patients (mean age 62.3 years, 241 [74.4%] males) were included in the final analysis. Overall, 13 patients demonstrated histologic progression to neoplasia over a mean follow-up of 3.7 years (progression risk 1.0% per year). The AUC of NLR for progression to high grade dysplasia (HGD) or EAC was 0.88 (95% confidence interval [CI] 0.83-0.96), and baseline NLR was associated with a 3-fold increase of progression to HGD and EAC during follow-up (hazard ratio [HR] 3.2, 95%CI 1.5-5.8; P <0.001). Notably, in a subgroup analysis of patients with nondysplastic BE (NDBE) at presentation, NLR was also a risk factor for histologic progression (HR 2.4, 95%CI 1.7-3.4; P <0.001). Conclusion NLR predicted histologic progression in patients with BE. Patients with NDBE and NLR above 2.4 can be considered for specific surveillance programs with shorter intervals between sessions.
引用
收藏
页码:774 / 781
页数:8
相关论文
共 50 条
  • [31] Durability of Cryoballoon Ablation in Neoplastic Barrett's Esophagus
    Dbouk, Mohamad
    Simons, Malorie
    Wang, Bingkai
    Rosenblum, Michael
    Gutierrez, Olaya I. Brewer
    Shin, Eun J.
    Ngamruengphong, Saowanee
    Voltaggio, Lysandra
    Montgomery, Elizabeth
    Canto, Marcia Irene
    TECHNIQUES AND INNOVATIONS IN GASTROINTESTINAL ENDOSCOPY, 2022, 24 (02): : 136 - 144
  • [32] High-fidelity DNA histograms in neoplastic progression in Barrett's esophagus
    Yu, Chenggong
    Zhang, Xiaoqi
    Huang, Qin
    Klein, Michael
    Goyal, Raj K.
    LABORATORY INVESTIGATION, 2007, 87 (05) : 466 - 472
  • [33] Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study
    Thota, Prashanthi N.
    Hajifathalian, Kaveh
    Benjamin, Tanmayee
    Runkana, Ashok
    Lopez, Rocio
    Sanaka, Madhusudhan R.
    JOURNAL OF DIGESTIVE DISEASES, 2017, 18 (03) : 143 - 150
  • [34] Clinical prediction model for tumor progression in Barrett's esophagus
    Holmberg, Dag
    Ness-Jensen, Eivind
    Mattsson, Fredrik
    Lagergren, Jesper
    SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES, 2019, 33 (09): : 2901 - 2908
  • [35] Risk stratification for synchronous/metachronous recurrence after endoscopic submucosal dissection for Barrett's esophageal adenocarcinoma using the length of Barrett's esophagus
    Ikenoyama, Yohei
    Namikawa, Ken
    Takamatsu, Manabu
    Kumazawa, Yusuke
    Tokai, Yoshitaka
    Yoshimizu, Shoichi
    Horiuchi, Yusuke
    Ishiyama, Akiyoshi
    Yoshio, Toshiyuki
    Hirasawa, Toshiaki
    Ogura, Toru
    Fujisaki, Junko
    ESOPHAGUS, 2024, 21 (03) : 357 - 364
  • [36] SOX2 as a Novel Marker to Predict Neoplastic Progression in Barrett's Esophagus
    van Olphen, Sophie
    Biermann, Katharina
    Spaander, Manon C. W.
    Kastelein, Florine
    Steyerberg, Ewout W.
    Stoop, Hans A.
    Bruno, Marco J.
    Looijenga, Leendert H. J.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (10) : 1420 - 1428
  • [37] Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
    Nguyen, Dang M.
    El-Serag, Hashem B.
    Henderson, Louise
    Stein, Daniel
    Bhattacharyya, Achyut
    Sampliner, Richard E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2009, 7 (12) : 1299 - 1304
  • [38] The utility of a genetic progression risk test for Barrett esophagus
    Gong, Dennis
    Lunz, Daniel
    Stover, James S.
    Meltzer, Stephen J.
    MEDICINE, 2022, 101 (37) : E30503
  • [39] The Aberrant Expression of Biomarkers and Risk Prediction for Neoplastic Changes in Barrett's Esophagus-Dysplasia
    Choi, Young
    Bedford, Andrew
    Pollack, Simcha
    CANCERS, 2024, 16 (13)
  • [40] Risk factors for Barrett's esophagus: a scoping review
    Ireland, Colin J.
    Thompson, Sarah K.
    Laws, Thomas A.
    Esterman, Adrian
    CANCER CAUSES & CONTROL, 2016, 27 (03) : 301 - 323